1 / 31

A review on Benzos

A review on Benzos. Gilles Fleury, MD, FRCPC Psychiatrist Montfort Hospital Assistant Professor Education Director – Division of addiction and mental health Department of Psychiatry University of Ottawa October 2016. Disclosure. No conflict of interest. Acknowledgements.

jop
Download Presentation

A review on Benzos

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A review on Benzos Gilles Fleury, MD, FRCPC Psychiatrist Montfort Hospital Assistant Professor Education Director – Division of addiction and mental health Department of Psychiatry University of Ottawa October 2016

  2. Disclosure • No conflict of interest

  3. Acknowledgements • Ralph Dell’Aquila MDCM, CCFP, MRO, ABAM and other presenters • Christine Landry, Pharmacist, Montfort Hospital, Ottawa, ON

  4. Objectives • Why can BZD use be problematic ? • When is BZD use problematic ? • What can we do about problematic BDZ use? • Describe detoxification approache Detox 101: How to Get Patients Off Benzo's and Alcohol  Idenfify whether your pafient is dependent on alcohol or benzo; Detox 101: How to Get Patients Off Benzo's and Alcohol  Develop a plan to help pafients taper and stop drinking;  Idenfify whether your pafient is dependent on alcohol or benzo; Detox 101: How to Get Patients Off Benzo's and Alcohol  Develop an approach to detox;  Develop a plan to help pafients taper and stop drinking;  Idenfify whether your pafient is dependent on alcohol or benzo;  Idenfify available resources for dependent pafients  Develop an approach to detox;  Develop a plan to help pafients taper and stop drinking;  Idenfify available resources for dependent pafients  Develop an approach to detox;  Idenfify available resources for dependent pafients

  5. Benzodiazepines (BZD): mechanism of action • Enhance GABA activity • GABA is the major inhibitory neurotransmitter of the CNS, it decreases neuronal excitation • GABAA : depressant effect • Benzodiazepine (Bz) receptors: • Bz1: Sleep-inducing effect • Site of action of zolpidem • Bz2 and Bz3 : antiseizure, antianxiety and muscle relaxation effects

  6. BZD - Therapeutic uses • Anticonvulsant • Muscle Relaxant • Cerebral palsy, dystonia • Amnesia with Sedation • Peri-operative or medical procedures • Alcohol withdrawal • Insomnia • Acute agitation

  7. BZD - Therapeutic uses -Psychiatric • Severe acute anxiety * Not first line treatment for anychronicanxietydisorder • Severegeneralizedanxietydisorderunresponsive to othertreatments • Panic disorder, social phobia • Adjunctivetreatment of depression, bipolar affective disorder and schizophrenia

  8. Benzodiazepines: Why taper? • Usually not because patient “addicted” • Possible benefits of tapering: • more alert, energetic • better able to make positive life changes • not need drug anymore • avoid future adverse effects • High risk if concomitant use of other depressants • Need to be aware of comorbid medical conditions and consider physiological stress to patients of tapering, patients with chronic medical conditions experience withdrawal more severely

  9. Benzodiazepines: Adverse Effects ACUTE • Sedation (depressant) • Decreasedrespiratory drive • Overdose (withotherdrugs - esp. alcohol and opioids) • Disinhibition CHRONIC • Decreased Neurocognition • Physiologic Dependency: Tolerance, Withdrawal • Addiction (Intoxication Syndromes)

  10. When is BZD use problematic? Risk Factors for BZD abuse • Comorbid substance use disorders • 80% of BZD abuse part of polydrug abuse • 40% of alcohol abuse • Psychiatric comorbidities: (PD, chemical coping) • Genetic vulnerability (tolerance) • Environmental factors • Pharmacodynamics of BZD (most reinforcing BZD)

  11. Risk Evaluation & Management Strategies Benzodiazepines—Side Effects, Abuse Risk and Alternatives Longo et al. Am FamPhysician. 2000 Apr 1;61(7):2121-2128. • Assessment of Risk Factors • Treatment Goals • Treatment Agreement • Care Plan • Medical Monitoring: • Reassess comorbidites & Diagnoses • How is Functional Status Progressing? • Progress in Behavioural Therapies ? • Management: Have a Plan to manage Complications

  12. Addressing problematic bdz use:Implement rems & safe prescribing guidelines • Other sedating drugs • COPD, sleep disorders • Elderly (esp long acting) • Liver dysfunction • Comorbidities are the rule, not the exception • If prescribing: careful assessment, care plan, Rx goals medical monitoring management: • Have a plan to reassess ++ & manage complications • Should clearly state intended short term nature and dependence potential

  13. Benzodiazepine withdrawal • The clinicalpicture looks like a reboundhyperexcitabilitywith: • body changes in a direction opposite to thatseenwith the first administration of the drug • Time course: • Acute syndrome: • For Short-acting BZDs (lorazepam, oxazepam), 3 to 7 days • Longer for longer acting drugs (e.g. diazepam) • Protractedwithdrawal: less intense symptoms for 3-6 months

  14. Benzodiazepine withdrawal • Symptoms are likely to include: • Headaches and anxiety (80%) • Insomnia (70%) • Tremors (60%) • Fatigue (60%) • Perceptual changes • Tinnitus • Sweating • Decrease concentration • Abrupt abstinence after higher doses could cause delirium and seizures

  15. Benzodiazepine (BDZ) Withdrawal SYMPTOMS • Anxiety-related (irritability, insomnia, panic attacks, hypersensitivity (photo/phono,touch) • Neurologic (tinnitus, distorted vision, dysperceptions, tremor) • Muscle twitching, insomnia, irritability, decreased concentration SIGNS / COMPLICATIONS • Autonomic hyperactivity (diaphoresis, tremor, tachycardia, HTN) • Hyperreflexia, • Mydriasis • Seizures, Arrythmias • Psychosis, Delirium • Suicidal Ideation

  16. BZD withdrawal Khong E, Sim MG, Hulse G.Benzodiazepine Dependence. Aust Fam Physician. 2004 Nov;33(11):923-6 • Factorsinfluencingseverity: • Duration of drug use • Doses used • Drug half-life • Individualpersonality style • Expectionsfrom patient and physician

  17. Treatment of BZD withdrawal • Good physical exam / screening investigations • Consider inpatient detoxification (hospital setting) • If using diazepam ≥ 60 mg / day OR unknown dosage • If outpatient, taper BZDs over 1 to 6 month-duration • On average, taper over 8 to 12 weeks • If too long, withdrawal becomes ‘the morbid focus of the patient’s existence’ • Either use the same BZD for taper or convert to long-acting (e.g. diazepam or chlordiazepoxide)

  18. Treatment of BZD withdrawal Converting to diazepam

  19. Treatment of BZD withdrawal • Treatment agreement on schedule and process • « weagreethat the goal iszero BZD » • Weekly dispensing of medication if necessary • No BZD PRN during the taper • Close monitoring of the patient during the taper • Monitor increasealcoholconsumtion/ otherdrug use • Non-pharmacological intervention for anxiety • Patient to keep a diary of symptoms and triggers • CBT (targetingunderlying condition) • Physical exercise • Relaxation techniques • Sleephygiene

  20. BZD withdrawal - schedule

  21. Basic principles in primary care Psychoeducation Techniques to deal with anxiety and insomnia Letter from the GP suggesting ↓ in the use of BZD Acknowledge that withdrawal could be stressful Advise changes in lifestyle such as physical activity Avoid stimulants and alcohol Refer to support group Refer to specialized program / agency

  22. Treatment of BZD withdrawal • Potential pharmacological agents to consider: • Carbamazepine: some evidence, but not enough to systematically recommend • 200 to 800 mg / day • Valproic acid (250 mg TID) / Gabapentin / Trazodone • SSRIs: if there is an underlying untreated anxiety / mood disorder • Was the patient depressed or anxious before the dependence? • Remember: • There is no medication approved for chronic insomnia

  23. Discontinuation

  24. Resources • benzo.org.uk by Professor Heather Ashton • information about the effects that BZDs have on the brain and body and how these actions are exerted • Detailed suggestions on how to withdraw after long-term use and individual tapering schedules for different BZDs are provided • http://www.open-pharmacy-research.ca/ • Deprescribing algorithm • Deprescribing.org

  25. Are z drugs addictive? Abuse and dependence of zopidem and zoplicone. Hajak et al. Addiction 2003 98:1371-78 Zoplicone: Is it a pharmacolgic agent for abuse? Cimolai, N. Cdn Family Physician Dec 2007:53(12) 2124-2129 • Z drugs: Zoplicone (Imovane), zolpidem (Ambien) • Non-BDZ • Onset: T1/2 • Abuse potential: lower than BDZ ; • incr risk in SUD & Psych

  26. Questions / Discussion Thank you!

  27. gfleury@montfort.on.ca Thank you

  28. References Denis et al. Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings. Cochrane Database Syst Rev. 2006 Jul 19;(3) Gould RL et al. Interventions for reducing benzodiazepine use in older people: meta-analysis of randomised controlled trials. Br J Psychiatry. 2014 Feb;204(2):98-107 Khong E, Sim MG, Hulse G.Benzodiazepine Dependence. Aust Fam Physician. 2004 Nov;33(11):923-6 Lader M1, Tylee A, Donoghue J. Withdrawing benzodiazepines in primary care. Expert Opin Investig Drugs. 2012 Jul;21(7):1019-29.

More Related